Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/β2-Glycoprotein I in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome.

Antiphospholipid antibodies (aPL), anti-beta 2-glycoprotein I (anti-beta 2-GPI) and anti-oxidized-low-density lipoprotein (LDL) antibodies are all implicated in the pathogenesis of antiphospholipid syndrome. To investigate whether different autoantibodies or combinations thereof produced distinct effects related to their antigenic specificities, we examined the frequencies of antiphospholipid s...

Libman-Sacks endocarditis in patients with systemic lupus erythematosus with secondary antiphospholipid syndrome

Background: Libman-Sacks endocarditis (LSE) is characterized by sterile lesions that commonly affect the aortic and mitral heart valves. Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) have been associated with LSE. Cardiac manifestations including LSE could be interrelated with other manifestations and early diagnosis could help in preventing further complications. Case...

Anti-b2-Glycoprotein I Autoantibodies from Patients with the “Antiphospholipid” Syndrome Bind to b2-Glycoprotein I with Low Affinity: Dimerization of b2-Glycoprotein I Induces a Significant Increase in Anti-b2-Glycoprotein I Antibody Affinity

Revisiting Beta 2 Glycoprotein I, the Major Autoantigen in the Antiphospholipid Syndrome

Beta 2 glycoprotein I (β2GPI) is a single chain 50 kDa highly glycosylated glycoprotein at an approximate concentration of 4 μM in cells. The abundance of this protein in plasma and its high state of preservation indicate the important role of this protein in mammalian. In addition, β2GPI has a particular structure in the fifth domain, and is categorized as the major antigen recognized by autoa...

Apoptotic antigens, B2-glycoprotein I, and antiphospholipid autoantibodies.